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Infection with the AIDS virus has led to an expanding
global health crisis, with over 45 million persons currently
living with HIV infection. Ineffective immune control and
resultant disease progression is a hallmark of this infection,
despite the induction of vigorous virus-specific CD8 T cell
responses in most infected persons. Although the features of
protective immunity in HIV infection remain to be defined,
growing evidence points to a critical role for virus-specific
CD4 cells. This is consistent with observations in murine
models that maintenance of effective antiviral CTL responses
in chronic viral infections is critically dependent on virus-
specific T helper cells (1–8).
A potentially simple explanation for the lack of effective
immune control in chronic HIV infection is that HIV selec-
tively infects activated CD4 cells and thereby destroys the
very cells being generated to coordinate the adaptive immune
response (9). However, simple deletion of antigen-specific
CD4 cells cannot be the reason for immune failure, since it
has been shown that large numbers of virus-specific CD4
cells that secrete interferon gamma (IFN-
 
 
 
) persist in most
persons with uncontrolled viremia (10–12). In contrast, the
ability of CD4 cells to proliferate in response to viral anti-
genic challenge is impaired in persons with progressive
infection and high viral loads (13–15). This apparent par-
adox implies the presence of a functional CD4 defect, the
definition of which is of critical importance in understanding
the immunologic control of viral replication.
A paper published by Younes et al. in this issue (16), and
a series of recent publications (17–19), provide new insights
into CD4 cells that are associated with lack of HIV immune
control and suggest that the presence of antigen-specific
CD4 cells able to produce IL-2 is a key component of effec-
tive immunity. Younes et al. examined virus-specific CD4
T cell responses in two groups of newly HIV-infected persons
(16). One group consisted of persons treated in the earliest
stages of acute infection in whom viremia was consistently
suppressed by effective antiviral therapy (aviremic subjects),
whereas a second group was likewise treated in the earliest
stages of acute infection but experienced persistent anti-
genic stimulation due to treatment interruptions or treat-
ment failure (viremic subjects). Focusing on persons treated
in acute infection makes sense, given that early treatment is
associated with generation of HIV-specific CD4 cell responses
(15, 20–23), and comparison of the two groups thus allowed
assessment of the role of persistent antigen exposure on
immune responses. Although both groups had readily detect-
able HIV-specific CD4 cell responses by intracellular IFN-
 
 
 
staining, there were striking differences in the ability of
these cells to produce IL-2. In aviremic subjects, the antigen-
specific cells not only produced IL-2 in addition to INF-
 
 
 
but also proliferated in vitro, as assessed in a flow cytometric
analysis in which decreases in CFSE labeling are indicative
of cell division. In viremic subjects, longitudinal analysis of
these responses in persons failing antiretroviral therapy
demonstrated that persistent exposure to virus was associated
with a marked decline in the proliferative capacity of HIV-
specific CD4 cells to undetectable levels (16). The defective
proliferative capacity of HIV-specific CD4 cells could be
corrected in vitro by the addition of exogenous IL-2 (16,
19), suggesting that HIV-specific CD4 cells in individuals
with persistent HIV infection are not simply deleted by
the virus but are deficient in their ability to produce IL-2
and proliferate.
These results, which demonstrate distinct subsets of HIV-
specific CD4 cells defined by proliferative capacity and ability
to produce IL-2 and/or IFN-
 
 
 
 in response to cognate antigen
exposure, are consistent with findings in murine models of
chronic viral infections and with data from several recent
human studies (17–19, 24, 25). In untreated HIV-infected
persons with progressive and nonprogressive disease, Harari
et al. recently reported three functionally distinct popula-
tions of CD4 cells: a subset secreting IL-2, a subset secreting
IFN-
 
 
 
, and a subset able to secrete both IL-2 and IFN-
 
 
 
 in
response to cognate antigen (18). In untreated persons with
progressive disease, the antigen-specific CD4 cells were
skewed toward those cells secreting IFN-
 
 
 
 alone, and IL-2–
secreting cells were almost absent, findings similar to those
of Younes et al. in their studies of treated viremic and
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aviremic subjects (16). Moreover, Harari et al. found a neg-
ative correlation between the frequencies of IL-2 and IL-2/
IFN-
 
 
 
–secreting CD4 cells and viral load (18). This same
relationship between viral load and CD4 cells secreting
both IFN-
 
 
 
 and IL-2 was recently reported by Boaz et al.
(17), suggesting a critical role of this specific population of
CD4 cells in viral containment. Other recent studies pro-
vide evidence that viremia directly impairs virus-specific
proliferative responses by showing that interruption in anti-
retroviral therapy and subsequent increased viremia in per-
sons with strong virus-specific CD4 proliferative responses
led to a loss of proliferative responses but not the ability to
secrete IFN-
 
 
 
 in an antigen-specific manner, and the pro-
liferative responses recovered rapidly with resuppression of
virmeia (14, 19). Coupled with the demonstration that vi-
rus-specific proliferative responses can be corrected in vitro
by the addition of exogenous IL-2, these studies provide
firm evidence that these cells are present but dysfunctional
(16, 19). However, the inability of IL-2 treatment of HIV-
infected persons to restore functional immunity suggests
that the relationship is not simple (26, 27).
The observed lack of IL-2–producing cells during persis-
tent HIV exposure is of particular interest in light of recent
studies regarding development of T cell memory. Memory
CD4 and CD8 cells can be divided into different sub-
sets based on their effector functions and migratory capac-
ity (28–30). T cells expressing the LN homing markers
L-selectin (CD62L) and CCR7 have been termed central
memory cells, whereas cells that are CD62L
 
 
 
/CCR7
 
 
 
have been termed effector memory cells and are thought to
have the capacity to migrate to sites of viral replication in
the tissues (Fig. 1). Central memory and effector memory
T cells have also been described to differ in their cytokine
production capacity, with central memory cells producing
predominately IL-2 and effector memory cells producing
both IFN-
 
 
 
 and IL-2 (28). The publications by Younes et
al. (16) and Harari et al. (18) indicate that HIV-specific
CD4 cells that produce IFN-
 
 
 
 alone or IFN-
 
 
 
 and IL-2
are CD45RA
 
 
 
/CCR7
 
 
 
 and are thought to have poor
proliferative capacity and thereby belong to the effector
memory subset. In contrast, HIV-specific CD4
 
 
 
/CD45RA
 
 
 
/
CCR7
 
 
 
 central memory cells produce primarily IL-2 after
stimulation with cognate antigen (16, 18) and are the sub-
set thought to be capable of rapid proliferation. The pres-
ence of persistent antigen in HIV-infected persons with
ongoing viremia is associated with a paucity of HIV-spe-
cific central memory CD4 cells compared with aviremic
individuals with suppressed viral loads. Similar findings
were reported recently in hepatitis C virus (HCV)–infected
humans using magnetic bead enrichment of CD4
 
 
 
/
tetramer
 
 
 
 cells, showing the phenotype of HCV-specific
CD4 cells to display a distinct CD45RA
 
 
 
/CCR7
 
 
 
 central
memory phenotype ex vivo in individuals with resolved
HCV infection (31).
These studies indicate that chronic antigen exposure
leads to impaired virus-specific CD4 T cell function. Pre-
vious studies in murine models of lymphocytic choriomen-
ingitis virus (LCMV) infection have indicated that LCMV-
specific CD4 cells lose the ability to produce IL-2 over
time in LCMV-infected perforin knockout mice that es-
tablish chronic infection compared with mice with acute
LCMV infection that is subsequently resolved (32). These
data are consistent with previous studies in murine models
of chronic viral infections, indicating loss of CD4 and CD8
T cell responsiveness, including decreased proliferation
and cytokine production, during the establishment of viral
persistence (33–35). Furthermore, chronically LCMV-
infected perforin knockout mice are able to maintain IFN-
 
 
 
–producing LCMV-specific CD4 cells, consistent with
the observations in the recently reported human studies of
HIV-infected individuals that maintain IFN-
 
 
 
–producing
but not IL-2–producing HIV-specific CD4 cells during
periods of viremia (16, 18, 19). It is interesting to note that
the impairment of proliferative responses in HIV-infected
individuals appears to be restricted to HIV-specific CD4
cells, as several studies have indicated no significant differ-
ence between proliferation to cytomegalovirus (CMV) or
other positive control antigens in persons with suppressed
or uncontrolled HIV viremia (14, 16, 19, 36). This may
possibly be due to the relative differences in CMV and
HIV viral loads, since CMV viral loads are often undetect-
able by current assays. Similar to the suppressed prolifera-
tive responses in individuals with high HIV viral loads,
persons with chronic HCV infection, which results in sim-
Figure 1. Potential model of the relationship between central and effector
memory cell differentiation and antigen load in chronic viral infections.
The presence of viral antigen drives the generation of effector memory cells
capable of producing IFN-  but lacking significant proliferative capacity,
which are short lived in vivo. Effector memory cells in turn drive down
antigen levels. Persistent exposure to high levels of antigen is thought to
drive differentiation to short lived effector cells and impair development of
central memory cells capable of proliferating and producing IL-2. 
Day and Walker
 
1775
ilar levels of uncontrolled viremia, display weak or absent
HCV-specific CD4 proliferative responses compared with
individuals with spontaneously resolved HCV infection
(37–39). Recent evidence in LCMV-infected mice indi-
cates the presence of antigen may drive the generation of
effector memory cells that convert to central memory cells
after antigen clearance, implying a complex and dynamic
relationship exists between the virus and host immune re-
sponse (40, 41).
The current findings are also of particular interest given
recent advances in understanding the role of CD4 cells in
the development of effective CD8 T cell responses. Al-
though the need for CD4 help in maintenance of effective
antiviral CD8 T cell responses has been known for some
time, recent studies in mice show that the development of
functional CD8 T cell memory is dependent on the pres-
ence of functional CD4 help during priming (2, 3, 5). CD4
cells are clearly dispensable for primary expansion of CD8 cells
during initial antigen encounter, but memory CD8 cells
capable of subsequent rapid expansion in response to sec-
ondary challenge are not generated. This notion is further
supported by recent reports in chimpanzee models of HCV
infection where the depletion of CD4 memory cells in im-
mune animals before reinfection resulted in persistent HCV
infection rather than clearance, and the emergence of viral
escape mutations in MHC class I–restricted epitopes (36).
These findings may have important implications in HIV in-
fection, since the HIV reverse transcriptase lacks proofread-
ing function and viral variants continue to arise in vivo.
Impaired CD4 responses during “priming” to these new
variants may contribute to the lack of effective long-term
immune control in this infection.
These studies describing a functional defect in virus-spe-
cific CD4 T cells may also help to explain the lack of effec-
tive antiviral CD8 T cell function in HIV infection. A re-
cent study in HIV-infected persons demonstrated a defect
in the ability of CD8 cells from persons with high viral
loads to expand upon encounter with antigen, suggesting a
potential link between dysfunctional CD8 cells and the
CD4 cell defects now being reported (42). Recent evi-
dence further indicates an important role of the expression
of the costimulatory molecule CD28 on antigen-specific
CD8 cells: restoration of CD28 expression on HIV and
CMV-specific CD28
 
 
 
/CD8
 
 
 
 cells reconstituted the ability
of these cells to produce IL-2 (43). However, the possible
link between expression of CD28 and IL-2 production by
antigen-specific CD4 cells remains to be defined. Such
studies need now to examine the relationship between the
proliferative capacity of CD8 cells and the presence of anti-
gen-specific IL-2–producing CD4 cells, which will require
assays that measure function of these cells rather than just
the ability to produce IFN-
 
 
 
. It is important to note that
multiple studies have failed to define differences in the fre-
quency of HIV-specific IFN-
 
 
 
–producing CD8 cells in
subjects with progressive and nonprogressive HIV infec-
tion, or to identify a correlation between frequencies of
HIV-specific CD8
 
 
 
/IFN-
 
  
 
 cells and viral load (10, 42,
 
44), similar to the lack of correlation between HIV-specific
CD4
 
 
 
/IFN-
 
  
 
 T cells and viral load (10, 18). Defin-
ing the relationship between IL-2–producing HIV-specific
CD4 cells and various parameters of frequency and func-
tion of HIV-specific CD8 T cell responses within the same
individuals may provide greater insight into the interactions
of CD4 and CD8 cells in chronic viral infections and the
contribution of subsets of virus-specific T cells with differ-
ent functional properties to the overall control of viremia.
Despite the important demonstration that chronic antigen
exposure such as persistent HIV viremia may suppress the
development of central memory cells capable of prolifer-
ating and producing IL-2, important questions remain.
Among these is the mechanism whereby high viral loads
suppress proliferation and IL-2 production by virus-specific
CD4 and CD8 cells. Recent evidence generated in mouse
studies has indicated effector memory cells producing IFN-
 
 
 
only, similar to that described in individuals with high
HIV viral loads (16, 18, 19), are short lived in vivo and do
not efficiently develop into long-term memory cells (40,
45). Since even prolonged antiviral therapy is associated
with only a partial recovery of IL-2–secreting virus-specific
CD4 cells (18, 19), it remains to be determined whether ad-
ditional approaches such as therapeutic immunization might
lead to an augmentation of these responder cells and
whether this would confer an antiviral benefit. The growing
body of evidence supporting the imperative role of CD4
cells in antiviral immunity underscores the importance of
boosting virus-specific CD4 memory cells in vaccine design
for the generation of effective immune control in chronic
viral infections and for the ultimate conquest of HIV.
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